BE705478A - - Google Patents
Info
- Publication number
- BE705478A BE705478A BE705478DA BE705478A BE 705478 A BE705478 A BE 705478A BE 705478D A BE705478D A BE 705478DA BE 705478 A BE705478 A BE 705478A
- Authority
- BE
- Belgium
- Prior art keywords
- emi
- good
- activity
- tolerance
- insomnia
- Prior art date
Links
- FBXGQDUVJBKEAJ-UHFFFAOYSA-N 4h-oxazin-3-one Chemical class O=C1CC=CON1 FBXGQDUVJBKEAJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 29
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 24
- 206010022437 insomnia Diseases 0.000 description 24
- 229940125717 barbiturate Drugs 0.000 description 9
- 230000002618 waking effect Effects 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 206010029216 Nervousness Diseases 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 5
- 229960002695 phenobarbital Drugs 0.000 description 5
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000147 hypnotic effect Effects 0.000 description 4
- 229960004815 meprobamate Drugs 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 4
- 229960002060 secobarbital Drugs 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940125725 tranquilizer Drugs 0.000 description 3
- 239000003204 tranquilizing agent Substances 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 229940072690 valium Drugs 0.000 description 2
- AJZJIYUOOJLBAU-CEAXSRTFSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n,n,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 AJZJIYUOOJLBAU-CEAXSRTFSA-N 0.000 description 1
- -1 (hypnotic) Chemical compound 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/215—Saturated compounds having only one carboxyl group and containing keto groups containing singly bound oxygen containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR81953A FR5948M (en:Method) | 1966-10-28 | 1966-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE705478A true BE705478A (en:Method) | 1968-03-01 |
Family
ID=8620138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE705478D BE705478A (en:Method) | 1966-10-28 | 1967-10-23 |
Country Status (3)
| Country | Link |
|---|---|
| BE (1) | BE705478A (en:Method) |
| DE (1) | DE1695907C3 (en:Method) |
| FR (1) | FR5948M (en:Method) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4936512B2 (ja) * | 2006-02-24 | 2012-05-23 | 公立大学法人大阪府立大学 | 光解裂性環状化合物 |
-
1966
- 1966-10-28 FR FR81953A patent/FR5948M/fr not_active Expired
-
1967
- 1967-10-23 BE BE705478D patent/BE705478A/fr not_active IP Right Cessation
- 1967-10-27 DE DE1967T0035128 patent/DE1695907C3/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE1695907C3 (de) | 1979-04-05 |
| DE1695907B2 (de) | 1978-08-03 |
| FR5948M (en:Method) | 1968-04-16 |
| DE1695907A1 (de) | 1971-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oswald et al. | Some experiments in the chemistry of normal sleep | |
| Mendelson | Human sleep and its disorders | |
| US12083090B2 (en) | Methods of using low-dose doxepin for the improvement of sleep | |
| US5565466A (en) | Methods for modulating the human sexual response | |
| Lhuintre et al. | Acamprosate appears to decrease alcohol intake in weaned alcoholics | |
| Stern et al. | Recent observations on the clinical pharmacology of (-) deprenyl | |
| JP2002538106A (ja) | イソバレルアミド、イソ吉草酸、または関連化合物を用いてｃｎｓ活性の調節に影響を与えることによる、痙縮および痙攣を含む様々な病状の治療 | |
| CH629479A5 (fr) | Derives de la taurine, medicament contenant ces derives et procede de preparation de ces derives. | |
| US5426120A (en) | Pharmaceutical composition containing γ-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders | |
| US20090042971A1 (en) | Method of using low-dose doxepin for the improvement of sleep | |
| RU2232016C2 (ru) | Изовалерамид-антиспастическое и противосудорожное средство, экстракт из растения семейства valerianaceae или хмеля - средство для лечения симптома спастичности и способ устранения этого симптома, способ лечения патологии, снимаемой центрально-опосредованным снижением мышечного тонуса | |
| Sögaard et al. | The effect of orally administered chlorpromazine on the electroencephalogram of man | |
| WO2002055070A1 (fr) | Tanshinones cycliques de dihydrofuranne utilisees pour le traitement de l'hyperammoniemie et de l'encephalopathie hepatique | |
| Berger et al. | Unusual muscle relaxant and analgesic properties of N-isopropyl-2-methyl-2-propyl-1, 3-propanediol dicarbamate (carisoprodol) | |
| BE705478A (en:Method) | ||
| Gim et al. | Percutaneous alcohol intoxication | |
| Bouchard et al. | Familial periodic ataxia responsive to acetazolamide | |
| CA2122780C (fr) | Utilisation de la selegiline en medecine veterinaire | |
| CH630803A5 (en) | Medicinal preparations, for the treatment of hypercholesterolaemia in particular | |
| KRAKOWSKI | Treatment of severe depression with desipramine, a metabolite of imipramine | |
| O'reilly et al. | Sustained-Release Nicotinic Acid (Nicospan): Effect on (1) Cholesterol Levels and (2) Leukocytes | |
| Bates | Winter poisoning hazards for pets | |
| Stuppy et al. | Treatment of hypertension with reserpine (Serpasil) alone and in combination with hydralazine (Apresoline) | |
| MOYER et al. | ELECTROLYTE, WATER, AND MERCURY EXCRETION AFTER ORAL ADMINISTRATION OF NEOHYDRIN: Observations on Experimental Use of Neohydrin (1347EX), a Chloro Derivative, and Two Thiol (1353EX and 1431EX) Derivatives of 2-Methoxy-Propylurea | |
| BE1000946A3 (fr) | Para-chloro-n-(3-morpholinopropyl) benzamide, son chlorhydrate, leur procede de preparation et medicament a action antidepressive et psychostimulatrice a base de chlorhydrate de cette substance. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE20 | Patent expired |
Owner name: FRANCO-CHIMIE S.P.R.L. Effective date: 19871023 |